Currently Viewing:
ISPOR 2019
Panelists Discuss the Potential and Pitfalls of Disruption in Healthcare
May 20, 2019
Trends in Value That Dr Daniel Mullins Expects to See in Coming Years
May 21, 2019
Dr Jon Campbell Discusses the Need for More Creative Methods of Value Assessment
May 21, 2019
The Imperfect QALY: How It's Used Depends on Where You Enter Value Discussions
May 21, 2019
Paul Melmeyer: Value Assessments Need to Take Into Account Unique Characteristics of a Disease
May 22, 2019
Panelists Debate the Role of ICER: Useful Overseer of Prices, or Oppressor of Choice?
May 22, 2019
Bringing Financial Theory Into the Value Equation of Future Cutting-Edge Therapies
May 22, 2019
Dr Devin Incerti Outlines Best Practices for Approaching Value Assessment
May 22, 2019
Biosimilar Experts Give Highlights of US Uptake Issues
May 23, 2019
Dr Nicholas Robert Explains the Benefits, Challenges of Using RWE for Measuring Clinical End Points
May 23, 2019
Currently Reading
Dr Eleanor Perfetto Outlines Criticisms of the QALY
May 23, 2019
Fremanezumab Cost Effective for Both Types of Migraine, Researchers Say
May 27, 2019
Dr Jon Campbell on Benefits of Using MCDA in Value Assessment
June 03, 2019
Dr Nicholas Robert Explains the Need to Standardize Use of RWE for Measuring Clinical End Points
June 23, 2019
Dr Devin Incerti: Use Value Assessments to Maximize the Well-Being of a Population
July 14, 2019
Dr Nicholas Robert Discusses How Real-World Data Can Complement Clinical Trial Data
July 16, 2019
Dr Eleanor Perfetto on Ways to Improve Transparency, Education Around Value Assessment
July 23, 2019
Dr Nicholas Robert on Lag Time Between Drug Approval, Availability of the Drug in EMRs
July 29, 2019
Dr Nicholas Robert: Lag Time Between a Drug Approval, Availability in EMRs Can Impact Patient Care
August 10, 2019
Dr Nicholas Robert Outlines How Patients Can Provide More Information on Newly Approved Drugs
August 22, 2019

Dr Eleanor Perfetto Outlines Criticisms of the QALY

Eleanor M. Perfetto, PhD, MS, senior vice president of Strategic Initiatives for the National Health Council, discusses criticisms of the quality-adjusted life year (QALY) and what factors the measure does not take into account.


Eleanor M. Perfetto, PhD, MS, senior vice president of Strategic Initiatives for the National Health Council, discusses criticisms of the quality-adjusted life year (QALY) and what factors the measure does not take into account.

Transcript

What are some criticisms of the QALY measure, and what factors does the measure not take into account that some argue it should?

Some of the limitations that the QALYs have are things like potentially being discriminatory against people who are older or people who have severe illnesses or disabilities, so those are things that need to be taken into consideration. Very often the QALY does not take into account patient views. So it’s really important that if a value assessment or a health technology assessment is going to be conducted that’s going to be using a QALY, the entire assessment should have patient input into it.

From the patient perspective, what concerns do they have with the QALY, and have there been efforts to try and include the patient voice into these measures?

One of the concerns that patients and patient groups have about the use of the QALY is that it might be used to prevent access to care or limited access to care, so that’s a major concern that if a QALY is being used by someone who is making a decision, that it be used in context with other elements and not alone and that a QALY shouldn’t be the decision maker.

In value assessment or in health technology assessment, there have been some efforts to include the patient voice. It’s really important that it be incorporated into the entire process and not be a check the box exercise that only happens at one point during the evaluation that’s happening. So, it’s really important that patients are at the table start to finish and having their voice heard.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up